Malaria

The device is targeted at severely ill malaria patients who have been hospitalised and prescribed IV drug treatment. These are the most vulnerable patients, including children, pregnant women and immune deficient patients, and can have mortality rates up to 20%.

Latest News

Xcelerate Startup Pitch Competition

Xcelerate Startup Pitch Competition
Created on 9/19/2018 11:00:24 AM

MediSieve presented at the Xcelerate Startup Pitch Competition at BioPharm America earlier this mon...
MediSieve welcomes Associate Biochemist to the team

MediSieve welcomes Associate Biochemist to the team
Created on 9/19/2018 10:46:49 AM

MediSieve is delighted to welcome Lucy Moran to the team. Lucy joins us as an Associate Bioche...